Advisory Alpha’s Teva Pharmaceuticals TEVA Stock Holding History

Advisory Alpha’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-645	Closed	-$6K	–	587
2020 Q3	$6K	Buy	+645	New	+$6.82K	﹤0.01%	501
2020 Q2	–	Sell	-4,045	Closed	-$41.2K	–	559
2020 Q1	$41.2K	Buy	4,045 +2,500	+162%	+$25.6K	0.01%	230
2019 Q4	$14.2K	Buy	1,545 +945	+158%	+$8.44K	﹤0.01%	450
2019 Q3	$3.92K	Buy	+600	New	+$4.6K	﹤0.01%	571
2019 Q2	–	Sell	-600	Closed	-$8.68K	–	582
2019 Q1	$8.68K	Buy	+600	New	+$10.6K	﹤0.01%	415

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Advisory Alpha's TEVA Position: Q4 2020 in Review

Advisory Alpha sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 645 shares — an estimated $6K sold.

Advisory Alpha first reported a position in TEVA in Q1 2019 and held it in 5 quarters. The position peaked at $41.2K in Q1 2020. 449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

Advisory Alpha reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 645 Teva Pharmaceuticals shares in Q4 2020, an estimated $6K.
Advisory Alpha first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 5 quarters.
Advisory Alpha's Teva Pharmaceuticals position peaked at $41.2K in Q1 2020.
449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.